Sosei Co., Ltd., a Japanese subsidiary of Sosei Group Corporation, has started a phase III trial for SO-1105 for the treatment of
oropharyngeal candidiasis. The study is an open-label, randomised, multiple centres, parallel-group design (With open active ...
[Published PharmaBiz - Mar 14 2013]